Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/9/2008 First Published: 1/11/2008


1.		Phase I/II Pilot Study of a Nonmyeloablative Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, Fludarabine Phosphate , and Low-Dose Total-Body Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Hematological Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				Under 100				Other				BCM-H-12472 H 12472, BCM-ACHE, NCT00056966


2.		Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) Given With CD45 Monoclonal Antibody (MAb) in Patients With Epstein Barr Virus (EBV) -Positive Nasopharyngeal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				Not specified				Other				20996 DELLA, NCT00515957

Last Modified: 10/9/2008 First Published: 1/29/2008


3.		Phase I Study of a Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, and Fludarabine Followed By Allogeneic Stem Cell Transplantation in Pediatric Patients With Severe Combined Immunodeficiency Disease or Other Primary Immunodeficiency Disorder

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				Under 18				Other				BCM-H-21123 H 21123, BCM-MASCI, NCT00609258

Last Modified: 5/19/2008 First Published: 1/31/2008


4.		Phase I Study of Anti-CD45 Monoclonal Antibody and Autologous or Syngeneic LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes in Patients With Relapsed Epstein-Barr Virus (EBV)-Positive Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or EBV-Associated T-/Natural Killer-Lymphoproliferative Disorders

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				Any age				Other				BCM-H19275 H 19275, BCM-ALDI, NCT00608478

Last Modified: 10/9/2008 First Published: 1/14/2008


5.		Phase I Study of Anti-CD45 Monoclonal Antibody, Cytarabine, Cyclophosphamide, and Total-Body Irradiation With or Without Alemtuzumab in Patients Undergoing Allogeneic Stem Cell Transplantation For Advanced Leukemia or Other Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				45 and under				Other				BCM-H-12870 H 12870, BCM-ADVL, NCT00601380

Last Modified: 12/9/2008 First Published: 1/31/2008


6.		Phase I Study of Anti-CD45 Monoclonal Antibody, 14g2a.zeta Chimeric Receptor Transduced Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes, and 14g2a.zeta Transduced Autologous Peripheral Blood T cells in Patients With Advanced Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				3 to 64				Other				BCM-H-13149 H 13149, BCM-NESTLES, NCT00609206


7.		A Phase I Trial Evaluating the Administration of Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) to Patients With Recurrent or Metastatic EBV-Positive Nasopharygneal Cancer (NPC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				NPC-CTL OCRN #03-NOV-0422, NCT00706316

Select All on One Page